Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Learn About Us
Background
DecorationDecoration

Latest news

Read more
Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

Read more

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Read more

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

Read more

BerGenBio ASA: Registration of share capital reduction

Read more

BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast

Read more

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

Read more

BerGenBio ASA: Grant of share options

Read more

BerGenBio ASA – Registration of reverse share split

Read more

BerGenBio ASA - Ex. reverse share split and change of ISIN today

Read more
All news